[Resistance to acetylsalicylic acid and clopidogrel: current status].
Resistance to acetylsalicylic acid (ASA) or clopidogrel is understood from the clinical point of view as failure of the drugs to prevent recurrent vascular occlusions. Non-response to ASA and clopidogrel is defined from the laboratory aspect as an inability to cause in vitro detectable platelet function inhibition. It would be beneficial to monitor non-response to ASA or clopidogrel with platelet function methods, which detect the specific effect of these drugs, and thus prevent clinical events caused by failure of therapy. Non-response to ASA and clopidogrel are detected with different platelet function methods, which are not always clinically standardized and are assessing only the global platelet function and not the specific drug effect. Although various studies reporting 5 to 59% non-response for both drugs, support a clinical relevance of ASA and clopidogrel non-response, well-designed clinical prospective trials are required to identify patients with antiplatelet drug resistance. Furthermore, mechanisms explaining this phenomenon of drug resistance are still unknown.
Mani
H
H
Johann-Wolfgang-Goethe-Universitätsklinik, Medizinische Klinik III, Schwerpunkt Angiologie, Theodor-Stern-Kai 7, 60590 Frankfurt am Main.
Lindhoff-Last
E
E
D001241:Aspirin / Q000627:therapeutic use*; D000077144:Clopidogrel; D016903:Drug Monitoring; D004351:Drug Resistance / Q000502:physiology*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014652:Vascular Diseases / Q000097:blood / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin